Volgende

Automatisch afspelen

AstraZeneca’s Immunotherapy Imjudo (tremelimumab) Wins FDA Approval for Liver Cancer

2 Bekeken • 06/28/23
Delen
insluiten
administrator
administrator
abonnees
0

AstraZeneca’s cancer immunotherapy Imjudo (tremelimumab) has won its first ever FDA approval after several trial setbacks in other cancers. The anti-CTLA-4 monoclonal antibody was approved in combination with the company’s PD-L1 inhibitor Imfinzi for the treatment of unresectable hepatocellular carcinoma, the most common type of liver cancer. The drug combination is also the first dual immunotherapy treatment regimen in liver cancer to receive FDA approval.

Visit Xtalks for more details on this story,
https://xtalks.com/astrazeneca....s-immunotherapy-imju

#shorts #AstraZeneca #Immunotherapy #Imjudo #Immuno-Oncology-Drug

Laat meer zien
0 Comments sort Sorteer op
Facebook Reacties

Volgende

Automatisch afspelen